参考文献
(在框内滑动手指即可浏览)
[1] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[2] Rumgay H,Arnold M,Ferlay J,et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J].J Hepatol,2022,77(6):1598-1606.
[3] Komuta M.Histological heterogeneity of primary liver cancers: Clinical relevance,diagnostic pitfalls and the pathologist's role[J].Cancers(Basel),2021,13(12):2871.
[4] Hepatocellular carcinoma.Hepatocellular carcinoma[J].Nat Rev Dis Primers,2021,7(1):7.
[5] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2024年版)[J].中国实用外科杂志,2024,44(4):361-386.
[6] 中国抗癌协会肝癌专业委员会.中国肿瘤整合诊治指南(CACA)-肝癌部分[J].肿瘤综合治疗电子杂志,2022,8(3):31-63.
[7] Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].JNCC,2024,4(1):47-53.
[8] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[9] Mcglynn KA,Petrick JL,El-Serag HB.Epidemiology of hepatocellular carcinoma[J].Hepatology,2021,73:4-13.
[10] Chuang SC,La Vecchia C,Boffetta P.Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection[J].Cancer Lett,2009,286(1):9-14.
[11] Chen X,Lu Y,Shi X,et al.Morbidity,prognostic factors,and competing risk nomogram for combined hepatocellular-cholangiocarcinoma[J].J Oncol,2021,2021:3002480.
[12] Zhou YM,Zhang XF,Wu LP,et al.Risk factors for combined hepatocellular-cholangiocarcinoma: A hospital-based case-control study[J].World J Gastroenterol,2014,20(35):12615-12620.
[13] Villanueva A.Hepatocellular Carcinoma[J].N Engl J Med,2019,380(15):1450-1462.
[14] Benson AB,D’angelica MI,Abrams T,et al.NCCN guidelines® insights: Biliary tract cancers,version 2.2023[J].JNCC,2023,21(7):694-704.
[15] Siddique O,Yoo ER,Perumpail RB,et al.The importance of a multidisciplinary approach to hepatocellular carcinoma[J].J Multidiscip Healthc,2017,10:95-100.
[16] Dyson J,Jaques B,Chattopadyhay D,et al.Hepatocellular cancer: The impact of obesity,type 2 diabetes and a multidisciplinary team[J].J Hepatol,2014,60(1):110-117.
[17] Jiang HT,Cao JY.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma[J].Chin Med Sci J,2015,30(2):80-83.
[18] 陈亚进,曹君.从创新到标准化:腹腔镜肝切除术进展和展望(1990-2020)[J].中国实用外科杂志,2020,40(2):158-162.
[19] 中国研究型医院学会肝胆胰外科专业委员会.腹腔镜肝切除术治疗肝细胞癌中国专家共识(2020 版)[J].中华消化外科杂志,2020,19(11):1119-1134.
[20] 梁霄,杨再博.腹腔镜肝癌切除术的肿瘤学风险及对策[J].中国实用外科杂志,2022,42(9):979-982.
[21] Pinato DJ,Sharma R,Allara E,et al.The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J].J Hepatol,2017,66(2):338-346.
[22] Demir T,Lee SS,Kaseb AO.Systemic therapy of liver cancer[J].Adv Cancer Res,2021,149:257-294.